Why it is necessary for homeopathic medicine to be paid for by the French National Insurance System for long term illnesses: examples from supportive care in oncology

Introduction

Since the 1 ^st January 2021, homeopathy is no longer paid for by the French National Insurance system. Without drug interference and significant side effects, popular with two-thirds of French people, homeopathy is by far the most used complementary medicine, whatever the disease. What is its real merit and what are the risks for patients with chronic conditions of having to pay for the actual cost of their medicine without any help from the French National insurance system?

Method

Review of the literature concerning the use of homeopathy in cancer care support.

Results

Homeopathy is the most widely used complementary medicine in oncology (30.7% of patients) with a very high percentage of satisfaction. The improvement in the quality of life has been shown in several studies. Better compliance with conventional cancer treatments has also made it possible to demonstrate an improvement in survival rates. Prescribed in 75% of cases by doctors, the use of homeopathy does not lead to refusal of treatment and is more and more often accepted or even recommended by oncologists. The latter are informed of these treatments in 83% of cases.

Discussion

The average prescription, respecting the recommendations of the International Homeopathic Society for Supportive Care in Oncology, is around € 50 per month. This can represent a medico-social handicap in long-term illnesses. Stopping or reducing homeopathy for economic reasons not only endangers the quality of life of these patients but also puts at risk their observance of conventional treatments with its consequent loss of opportunity.

Conclusion

We believe it is essential and urgent for the French national insurance system to return to paying for homeopathy in the framework of supportive care for long-term illnesses.